ProMIS Neurosciences, Inc.
NASDAQ:PMNBiotechnology
-$0.02 today
- Market cap
- $99.36M
- Beta
- -0.22
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$4.62
Volume 0.13M
Average 0.07M
PMN Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
ProMIS Neurosciences, Inc.NASDAQ: PMN
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization outflow grows to $0
Q2 FY2026 depreciation & amortization was $0, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $0.
Context
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
Mixed currencies · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 21.16K | — |
| FY2022 | 2022-12-31 | 15.07K | -67.6% |
| FY2021 | 2021-12-31 | 46.46K | — |
Depreciation & Amortization vs competitors
How PMN compares with its peers on the latest reported figures
- PMN's LTM Jun 2026 depreciation & amortization of $0 is the smallest of the 4 companies compared; the peer median is $574K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2024 | $2.04M | — | -11.5% | 31.4% | |
| LTM Mar 2026 | $574K | -20.3% | +0.2% | — | |
| LTM Mar 2026 | $120.64K | -26.1% | +0.3% | — | |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding PMN) | $574K | -23.2% | +0.2% | 31.4% | |
Competitors are the stored peer set for PMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CAD | FY2022 Dec 2022 · CAD | FY2023 Dec 2023 · USD | FY2024 Dec 2024 · USD | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (9.4M) | (24.27M) | (13.21M) | 2.78M | (39.72M) |
| Depreciation & Amortization | 46.46K | 15.07K | 21.16K | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 655.2K | 271.54K | 825.81K | 857.63K |
| Change in Working Capital | (1.59M) | 7.26M | 2.94M | (11.73M) | 10.75M |
| Accounts Receivables | (17.57K) | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (32.09K) | 3.6M | 4.96M | (6.11M) | 805.95K |
| Other Working Capital | (1.54M) | 3.66M | (2.02M) | (5.62M) | 9.94M |
| Other Non-Cash Items | 1.5M | (6.55M) | (868.56K) | (19.06M) | (5.59K) |
| Operating Cash Flow | (9.44M) | (22.89M) | (10.84M) | (27.18M) | (28.12M) |
| Capital Expenditures | (6.12K) | (2.66K) | 0 | 0 | 0 |
| Acquisitions (Net) | 99.7K | 0 | 0 | 0 | 0 |
| Purchases of Investments | (33.56K) | (41.67K) | (32.36K) | (33.05K) | (33.75K) |
| Sales of Investments | 35.92K | 41.67K | 31.01K | 32.36K | 33.05K |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 95.93K | (2.66K) | (1.35K) | (693) | (702) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 25.63M | 6.68M | 17.75M | 27.85M | 20.94M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 2.04M | 3.6K | 28.04K | 0 |
| Financing Cash Flow | 25.63M | 8.73M | 17.75M | 27.88M | 20.94M |
| Effect of Forex Changes | (114.46K) | (707.96K) | (181.43K) | 0 | 0 |
| Net Change in Cash | 16.17M | (14.87M) | 6.72M | 693.02K | (7.17M) |
| Free Cash Flow | (9.45M) | (22.89M) | (10.84M) | (27.18M) | (28.12M) |
ProMIS Neurosciences, Inc.
NASDAQ:PMN
Intrinsic Alpha fair value
Locked
Current Price
$11.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.